Kymera Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing oral small molecule degraders through targeted protein degradation. Its Form 8-K reports cover material events such as operating and financial results, clinical and regulatory disclosures, Regulation FD presentations, collaboration-related updates, and capital-raising arrangements involving common stock.
Proxy and governance filings describe shareholder voting matters, executive compensation, equity awards, board oversight, and bylaw provisions, including forum-selection language. The filing record also identifies KYMR common stock and recurring disclosure areas tied to the company’s pipeline, financing capacity, corporate governance, and public-company reporting obligations.
Kymera Therapeutics, Inc. (KYMR), a clinical-stage biopharmaceutical company developing targeted protein degraders, reported collaboration revenue of $0 for the three months ended September 30, 2026, versus $2.764 million a year earlier; research and development expense was $128.509 million versus $74.094 million, and net loss was $131.999 million versus $82.175 million. For the first nine months, collaboration revenue was $99.365 million, up from $36.341 million, while net loss was $262.444 million compared with $224.370 million. Nine-month revenue included $79.4 million under the Gilead agreement and a $20.0 million Sanofi milestone.
Cash, cash equivalents and marketable securities totaled $1,646 million as of September 30, 2026; Kymera said these resources were expected to fund operations and capital expenditures through at least twelve months from issuance of the financial statements. Operating cash used was $220.818 million for the nine months. Under its at-the-market sales agreement, Kymera sold 2,032,140 shares for approximately $219.9 million in gross proceeds.
Kymera Therapeutics, Inc. reported third-quarter 2026 results and clinical updates, including positive Phase 1 healthy-volunteer results for KT-579. The trial showed ≥90% median IRF5 degradation across multiple dose levels; analyses using the median of all MAD dose cohorts showed inhibition at Day 14 of 88% of TNFα, 87% of IL-12/23p40, 94% of IL-1β and 98% of IFNβ. No serious or severe adverse events occurred, and no adverse events led to discontinuation.
For the quarter, collaboration revenue was $0 versus $2.764 million in third-quarter 2025; research and development expenses were $128.509 million versus $74.094 million, and net loss was $131.999 million versus $82.175 million. Cash, cash equivalents and marketable securities totaled $1,645.883 million as of September 30, 2026, with expected cash runway into 2029.
In KT-621, the last patient completed the week 16 visit in the BROADEN2 Phase 2b atopic dermatitis trial; topline data are planned by year-end 2026. The company expects BREADTH asthma topline data in late 2027 and plans to start the KT-579 LUMORA lupus Phase 1b trial by early 2027. It expects to initiate a Phase 3 atopic dermatitis trial by mid-2027, subject to discussions with regulators.
For Kymera Therapeutics, Inc. (KYMR), BlackRock, Inc. reported beneficial ownership of 5,450,286 shares of common stock, or 6.6%, as of September 30, 2026. The reported position reflects securities beneficially owned or deemed beneficially owned by certain BlackRock business units and subsidiaries and affiliates; other business units whose holdings are disaggregated from that group are excluded.
BlackRock reported sole voting power over 5,331,553 shares and sole dispositive power over 5,450,286 shares, with no shared voting or dispositive power. Various persons may receive dividends or sale proceeds, but no one person's interest exceeds 5% of Kymera's outstanding common shares.
Kymera Therapeutics, Inc. (KYMR) Chief Executive Officer Nello Mainolfi exercised options for 30,000 shares on October 1, 2026, at $2.08 per share, acquiring 30,000 common shares. He sold 30,000 common shares in six transactions; the reported weighted-average prices for the lots were $111.44, $112.42, $113.24, $114.43, $115.40, and $116.12. The option position was 60,000 shares after exercise. The transactions were made under a Rule 10b5-1 plan adopted March 24, 2026.
Kymera Therapeutics, Inc. (KYMR) is named in a notice that Nello Mainolfi, identified as an officer and director, intends to sell 30,000 common shares through UBS Financial Services, Inc., with an approximate sale date of October 1, 2026. The notice lists an aggregate market value of $3,353,700. The shares are listed as acquired from the issuer through exercise of stock options on October 1, 2026, with cash payment.
Kymera Therapeutics, Inc. (KYMR) is the subject of an amended Schedule 13G filing in which T. Rowe Price Associates, Inc. reports beneficial ownership of 8,873,588 shares of common stock, representing 10.7% of the class as of August 31, 2026.
T. Rowe Price Associates reports sole voting power over 8,821,580 shares and sole dispositive power over 8,873,588 shares, with no shared voting or dispositive power. T. Rowe Price Associates states that the filing should not be construed as an admission that it is the beneficial owner of these securities, and such beneficial ownership is expressly denied.
Kymera Therapeutics, Inc. (KYMR) reported that Chief Legal Officer Brian Adams sold a total of 6,371 shares of common stock on September 4, 2026. The company states these sales were required to cover tax withholding obligations upon vesting of restricted stock units and occurred automatically, not at his discretion. No Rule 10b5-1 trading plan is reported.
Kymera Therapeutics, Inc. (KYMR) is the issuer for a Form 144 notice filed for the potential sale of up to 6,371 shares of its common stock for the account of officer Brian Adams. The shares were acquired on September 3, 2026 upon vesting of Restricted Stock Units under Kymera’s 2020 Equity Incentive Plan.
The notice states that the sales are intended to cover tax withholding obligations related to the RSU vesting, will be executed through Morgan Stanley Smith Barney LLC, and were automatic transactions intended to qualify under Rule 10b5-1.
Kymera Therapeutics, Inc. (KYMR) is the issuer for which officer Jeremy Chadwick has filed a notice of proposed sale of common stock under Rule 144. The notice covers 10,879 shares of common stock to be sold on or after September 2, 2026, through Morgan Stanley Smith Barney, with the shares being acquired via exercise of stock options and sold for cash over the next three months.
In the prior three months, Chadwick reported additional Rule 144 sales of Kymera common stock, including 12,500 shares for $1,222,072.50 on June 23, 2026, 5,510 shares for $499,646.80 on June 18, 2026, and 48,883 shares for $4,410,837.77 on June 17, 2026, each identified as 10b5-1 sales.
T. Rowe Price Associates, Inc. reported its holdings in Kymera Therapeutics Inc. (common stock) on an amended beneficial ownership report. The firm reported beneficial ownership of 7,112,345 shares, representing 8.6% of the common stock as of June 30, 2026. It reported sole voting power over 7,086,948 shares and sole dispositive power over 7,112,345 shares, with no shared voting or dispositive power. T. Rowe Price Associates stated that this filing should not be construed as an admission that it is the beneficial owner of these securities and expressly denied such beneficial ownership.